Arcus Biosciences (RCUS) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Upcoming data catalysts

• Two major data sets expected before year-end: ARC-20 (Casdatifan, HIF-2 alpha inhibitor) and ARC-10 (Domvanalimab, Fc-silent TIGIT antibody).

• ARC-20 data to be presented at the Triple Meeting in Barcelona, including 100 mg and 50 mg expansion cohorts with key efficacy and durability metrics.

• ARC-10 phase 3 data, despite early termination, will provide randomized results for Dom plus Zim versus Zim versus chemo, with two years of follow-up.

• Both data sets are expected to inspire confidence due to consistency and differentiation from competitors.

• Additional data presentations from ongoing studies are planned for future conferences.

Portfolio strategy and pipeline evolution

• Portfolio is diversifying beyond IO, with increasing focus on cell-intrinsic targets and inflammation.

• New programs include an AXL inhibitor for lung cancer and other cell-intrinsic molecules, with more details expected over the next year.

• Expansion into inflammation leverages in-house expertise from prior experience.

• Drug discovery engine enables flexibility and ongoing diversification.

Competitive landscape and differentiation

• Recent competitor data (NiKang, Merck) in HIF-2 alpha space seen as favorable, with Merck's belzutifan as main competitor.

• Key efficacy benchmarks: primary progressive disease, ORR, and PFS; current data trends suggest potential to outperform belzutifan.

• Safety profile aims to match belzutifan, with focus on manageable on-target toxicities.

• Dose optimization strategy aligns with regulatory expectations and supports robust data generation.